Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/KDM2A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/KDM2A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/KDM2A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/KDM2A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/KDM2A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/KDM2A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/KDM2A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/KDM2A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/KDM2A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/KDM2A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/KDM2A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00485114 | Colorectum | CRC | rhythmic process | 64/2078 | 298/18723 | 1.43e-07 | 1.62e-05 | 64 |
GO:00076234 | Colorectum | CRC | circadian rhythm | 47/2078 | 210/18723 | 1.89e-06 | 9.29e-05 | 47 |
GO:00427524 | Colorectum | CRC | regulation of circadian rhythm | 28/2078 | 121/18723 | 1.17e-04 | 2.29e-03 | 28 |
GO:00165702 | Colorectum | CRC | histone modification | 75/2078 | 463/18723 | 4.95e-04 | 7.06e-03 | 75 |
GO:00485119 | Endometrium | AEH | rhythmic process | 67/2100 | 298/18723 | 1.69e-08 | 1.04e-06 | 67 |
GO:00076239 | Endometrium | AEH | circadian rhythm | 47/2100 | 210/18723 | 2.54e-06 | 7.28e-05 | 47 |
GO:00329227 | Endometrium | AEH | circadian regulation of gene expression | 22/2100 | 68/18723 | 2.65e-06 | 7.57e-05 | 22 |
GO:00427527 | Endometrium | AEH | regulation of circadian rhythm | 25/2100 | 121/18723 | 1.79e-03 | 1.43e-02 | 25 |
GO:0010944 | Endometrium | AEH | negative regulation of transcription by competitive promoter binding | 5/2100 | 10/18723 | 2.74e-03 | 1.97e-02 | 5 |
GO:004851114 | Endometrium | EEC | rhythmic process | 67/2168 | 298/18723 | 5.86e-08 | 3.11e-06 | 67 |
GO:003292212 | Endometrium | EEC | circadian regulation of gene expression | 22/2168 | 68/18723 | 4.49e-06 | 1.14e-04 | 22 |
GO:000762314 | Endometrium | EEC | circadian rhythm | 46/2168 | 210/18723 | 1.37e-05 | 2.73e-04 | 46 |
GO:00109441 | Endometrium | EEC | negative regulation of transcription by competitive promoter binding | 5/2168 | 10/18723 | 3.16e-03 | 2.16e-02 | 5 |
GO:004275213 | Endometrium | EEC | regulation of circadian rhythm | 24/2168 | 121/18723 | 5.69e-03 | 3.42e-02 | 24 |
GO:00165708 | Esophagus | HGIN | histone modification | 92/2587 | 463/18723 | 1.70e-04 | 3.30e-03 | 92 |
GO:003292210 | Esophagus | HGIN | circadian regulation of gene expression | 20/2587 | 68/18723 | 6.35e-04 | 8.73e-03 | 20 |
GO:000762318 | Esophagus | HGIN | circadian rhythm | 45/2587 | 210/18723 | 1.60e-03 | 1.79e-02 | 45 |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
GO:003292215 | Esophagus | ESCC | circadian regulation of gene expression | 48/8552 | 68/18723 | 2.76e-05 | 2.30e-04 | 48 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KDM2A | SNV | Missense_Mutation | rs746832356 | c.2384G>A | p.Arg795Gln | p.R795Q | Q9Y2K7 | protein_coding | tolerated(0.21) | benign(0.06) | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
KDM2A | SNV | Missense_Mutation | | c.1318G>A | p.Asp440Asn | p.D440N | Q9Y2K7 | protein_coding | tolerated(0.48) | benign(0.01) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KDM2A | SNV | Missense_Mutation | rs779790225 | c.59N>A | p.Arg20Gln | p.R20Q | Q9Y2K7 | protein_coding | tolerated(0.18) | possibly_damaging(0.449) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KDM2A | SNV | Missense_Mutation | | c.1126N>A | p.Glu376Lys | p.E376K | Q9Y2K7 | protein_coding | tolerated(0.2) | benign(0.011) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KDM2A | SNV | Missense_Mutation | | c.2987N>A | p.Ser996Asn | p.S996N | Q9Y2K7 | protein_coding | deleterious(0) | benign(0.346) | TCGA-E2-A1B0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
KDM2A | SNV | Missense_Mutation | novel | c.1228N>C | p.Thr410Pro | p.T410P | Q9Y2K7 | protein_coding | tolerated(0.28) | benign(0.013) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
KDM2A | SNV | Missense_Mutation | novel | c.1603N>G | p.Ile535Val | p.I535V | Q9Y2K7 | protein_coding | tolerated(0.43) | benign(0.005) | TCGA-E9-A5UO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KDM2A | SNV | Missense_Mutation | | c.1307G>A | p.Gly436Glu | p.G436E | Q9Y2K7 | protein_coding | tolerated(0.96) | benign(0.007) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
KDM2A | SNV | Missense_Mutation | novel | c.2089N>A | p.Val697Met | p.V697M | Q9Y2K7 | protein_coding | tolerated(0.22) | benign(0.06) | TCGA-XX-A899-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
KDM2A | insertion | In_Frame_Ins | novel | c.621_622insAAAATAAAAATAAACATTTTTATTATTTAT | p.Cys207_Tyr208insLysIleLysIleAsnIlePheIleIleTyr | p.C207_Y208insKIKINIFIIY | Q9Y2K7 | protein_coding | | | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |